Aligos Therapeutics, Inc.
About Aligos Therapeutics, Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.2M
- Net income
- -$24.2M
- Total assets
- $88.5M
- Market cap
- $30.4M
- Operating margin
- -4024.9%
- Net margin
- -1106.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.2M
- Operating expenses
- $90.2M
- Operating income
- -$88.0M
- Income tax
- $314.0K
- Net income
- -$24.2M
- EPS (basic)
- $-2.45
- EPS (diluted)
- $-2.45
Balance sheet
- Total assets
- $88.5M
- Current assets
- $82.9M
- Total liabilities
- $35.0M
- Current liabilities
- $21.2M
- Shareholders’ equity
- $53.5M
Cash flow
- Operating cash flow
- -$82.5M
- Investing cash flow
- -$37.8M
- Financing cash flow
- $101.6M
- Net cash flow
- -$18.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $30.4M
- EPS (diluted)
- $-2.45
- Shares outstanding
- 6.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 16, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $24.2M in FY2025.
- Revenue declined 50% from FY2021 to FY2025.
- Trading 63% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aligos Therapeutics, Inc..
Write a review
News about Aligos Therapeutics, Inc.
News & sentiment via Polygon.io
